This is a preview of subscription content, log in via an institution to check access.
References
Tefferi A et al (2009) Myelodysplastic syndromes. N Engl J Med 361:1872–1885
Fisch P et al (2000) Pure red cell aplasia. Br J Haematol 111:1010–1022
Ammus SS et al (1987) Acquired pure red cell aplasia. Am J Hematol 24:311–326
Sawada K et al (2008) Acquired pure red cell aplasia : updated review of treatment. Br J Haematol 142(4):505–14
Williamson PJ et al (1991) Red cell aplasia in myelodysplastic syndrome. J Clin Pathol 44:431–432
Garcia-Suarez J et al (1998) Myelodysplastic syndrome with erythroid hypoplasia/aplasia : a case report and review of the literature. Am J Hematol 58:316–325
Abkhowitz JL et al (1986) Pure red cell aplasia : lymphocyte inhibition of erythropoiesis. Br J Heamatol 63:59–62
Biesma DH et al (1997) Immunosuppressive therapy for hypoplastic myelodysplastic syndrome. Cancer 79:1548–1551
Kim H et al (2009) A pilot dose-escalating study of alemtuzumab plus cyclosporine for patients with bone marrow failure syndrome. Leuk Res 33(2):222–31
List A et al (2006) Lenalidomide in the myelodysplastic syndrome with chromosome 5q deletion. N Engl J Med 355(14):1456–65
Conflict of interest
The authors declare that they have no conflict of interest.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Cerchione, C., Catalano, L., Cerciello, G. et al. Role of lenalidomide in the management of myelodysplastic syndromes with del(5q) associated with pure red cell aplasia (PRCA). Ann Hematol 94, 531–534 (2015). https://doi.org/10.1007/s00277-014-2192-z
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00277-014-2192-z